Phio Pharmaceuticals Corp
$ 1.05
0.96%
27 Jul - close price
- Market Cap 12,081,900 USD
- Current Price $ 1.05
- High / Low $ 1.07 / 1.03
- Stock P/E N/A
- Book Value 1.42
- EPS -1.38
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.47 %
- ROE -0.76 %
- 52 Week High 2.70
- 52 Week Low 0.81
About
Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-20 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.34 | -0.15 | -0.44 | -0.45 | -0.41 | -0.85 | -1.54 | -3.62 | -1.53 | -0.85 | -10.26 | -1.4747 |
| Estimated EPS | -0.23 | -0.47 | -0.44 | -0.36 | None | -1.23 | -4.14 | -4.59 | -11.7 | -1.3 | -12.87 | None |
| Surprise | -0.11 | 0.32 | 0 | -0.09 | 0 | 0.38 | 2.6 | 0.97 | 10.17 | 0.45 | 2.61 | 0 |
| Surprise Percentage | -47.8261% | 68.0851% | 0% | -25% | None% | 30.8943% | 62.8019% | 21.1329% | 86.9231% | 34.6154% | 20.2797% | None% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHIO
2026-07-27 00:42:36
This article provides a detailed financial overview of Phio Pharmaceuticals Corp (PHIO), including its income statement, balance sheet, and cash flow statement, up to FY2025. It highlights recent earnings, revenue, and EPS figures, along with year-on-year changes for various financial indicators. The report also addresses frequently asked questions about the company's assets, liabilities, equity, and profitability.
2026-07-26 21:40:11
The article provides an earnings forecast for Phio Pharmaceuticals Corp (PHIO), noting its current earnings forecast score of 8.00, which ranks 168th in the Biotechnology & Medical Research industry. Analysts project a price target of $14.00 for PHIO, suggesting a significant upside. The analyst rating is predominantly "Buy," based on one analyst's assessment.
2026-07-26 16:40:11
This page provides a detailed balance sheet for Phio Pharmaceuticals Corp (PHIO), offering both quarterly and annual data for evaluating the company's financial health. It includes key financial metrics such as cash and short-term investments, total assets, current assets, liabilities, and shareholders' equity, along with historical percentage changes for each item. The article also provides a FAQ section answering common questions about balance sheet analysis for PHIO.
2026-07-25 11:12:17
This article provides a technical analysis of Phio Pharmaceuticals Corp (PHIO), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. PHIO currently has a price momentum score of 4.96, ranking 142nd in its industry, trading between a resistance of 1.17 and support of 0.87. While indicators show mixed signals (2 sell, 4 neutral, 1 buy), moving averages suggest a neutral signal overall.
2026-07-24 14:42:58
This article provides a link to Phio Pharmaceuticals Corp.'s (NASDAQ: PHIO) revenue breakdown on TradingView. It indicates that the market was closed at the time of viewing and offers various financial and analytical tools for the company. The page also includes general information about TradingView's offerings and services.
2026-07-24 13:42:58
Phio Pharmaceuticals Corp (PHIO) is a clinical-stage biotechnology company focused on developing therapeutics for cancer treatment using its INTASYL self-delivering RNAi technology. The company's pipeline includes PH-762 and PH-894, targeting PD-1 and BRD4 respectively, to enhance the immune system's ability to fight tumors. The article also provides corporate information, executive details, and institutional shareholder data for the company.
